Aurobindo Pharma Q4 FY26: Europe strength offsets a softer US quarter

Aurobindo Pharma closed Q4 FY26 with steady growth and a clear message on priorities: keep the base generics franchise resilient while funding the next leg of biologics and biosimilars. Revenue from operations rose to ₹8,853 crore, up 5.6 percent year on year. EBITDA came in at ₹1,801 crore, up 0.5 percent, with an EBITDA margin of 20.3 percent. Profit after tax increased to ₹921 crore, up 2.0 percent.

The quarter was not built on one-off wins. Management pointed out that the US base business stayed stable even without transient product sales, and that Europe carried much of the growth. The mix shift shows up in the regional performance numbers and in the margin bridge. Gross margin improved to 61.3 percent, up 216 basis points year on year, but higher overheads and operating costs meant EBITDA growth was modest.

The quarter in context: stable profits, mixed regional signals

Q4 FY26 continued the pattern seen across FY26: revenue growth has been positive, but the earnings profile is being shaped by investment choices, currency movements, and market mix. Compared with Q4 FY25, gross profit grew faster than revenue, supported by better gross margin. At the same time, overheads rose 14.6 percent year on year, which limited operating leverage.

The regional story is sharper than the consolidated view. Europe expanded strongly, while the US declined. Growth Markets and ARV contributed incremental growth, and API showed a rebound in the quarter even though FY26 API revenues were lower than FY25.

Aurobindo also highlighted cash discipline and balance sheet strength. Free cashflows generated were $35 million during the quarter, and net cash including investments stood at about$317 million as on March 31, 2026, even after cash payment for the Khandelwal Labs acquisition.

Financial snapshot

Segment performance: Europe drives, US resets, API rebounds

The formulation business, which remains the core earnings engine, grew 4.6 percent year on year in Q4 FY26 to ₹7,646 crore. Within formulations, Europe was the standout. European revenue rose to ₹2,795 crore in Q4 FY26, up 30.2 percent year on year and 3.4 percent sequentially. Management described performance as strong across key markets, and the reported euro revenue held steady sequentially at EUR 261 million.

The US formulation business told a different story. US revenue was ₹3,543 crore, down 13.0 percent year on year. In dollar terms, US revenue declined from $470 million in Q4 FY25 to$387 million in Q4 FY26. Aurobindo attributed the sequential decline largely to seasonality and noted that the base business remained stable despite lower transient product sales. Operational activity continued, with 12 launches and 9 approvals during the quarter.

Growth Markets remained supportive. Revenue increased to ₹980 crore, up 24.7 percent year on year and 13.3 percent quarter on quarter. The company linked the growth to strong performance across markets. Domestic formulations were a small component, with ₹76 crore in Q4 FY26.

The ARV business grew 6.4 percent year on year to ₹328 crore, but declined sequentially, which management linked to tender timing. This reinforces a recurring theme in ARV: quarterly movements can be more about tenders than underlying demand.

On the manufacturing and API side, the picture was mixed. API revenue rose 12.9 percent year on year in Q4 FY26 to ₹1,208 crore, with management highlighting volume growth in the non-antibiotics segment. Yet for the full year, API revenue was ₹4,047 crore, down 6.4 percent year on year. Within APIs, beta-lactam declined for both the quarter and year, while non beta-lactam showed sharp quarterly growth. The near-term signal is that the API portfolio is improving in mix and volumes in non-antibiotics, but the year-on-year decline suggests the recovery is still uneven.

Segment mix view for Q4 FY26

Margin and cash: gross improvement, costs and FX shape EBITDA

The income statement highlights a clear trade-off. Gross margin improved meaningfully, but overhead growth and FX effects reduced the flow-through.

Gross profit increased to ₹5,424 crore, up 9.5 percent year on year, and gross margin rose to 61.3 percent. Overheads, however, increased to ₹3,623 crore, up 14.6 percent. EBITDA margin declined to 20.3 percent from 21.4 percent, even though EBITDA held largely flat year on year.

Below EBITDA, finance costs improved. Finance cost declined to ₹98 crore from ₹115 crore year on year for the quarter, and for FY26 it reduced to ₹384 crore from ₹457 crore. Depreciation rose, consistent with ongoing investment, and other income declined year on year.

Cash flow was positive but lower than earlier quarters. Cash flows before dividend and buyback were $35 million in Q4 FY26, compared with$118 million in Q3 FY26 and $131 million in Q4 FY25. The quarter included payment for the Khandelwal Labs non-oncology business acquisition of$32 million.

The balance sheet narrative remains conservative. Gross debt as of March 2026 was $809 million, and net cash including investments was about$317 million. In INR terms, cash balance and investments stood at ₹10,676 crore, and net cash was ₹3,002 crore. Management also provided a net debt movement bridge for Q4 FY26, showing business cash flow after working capital of $149 million and free cash flow from business of$96 million, followed by investments and capex allocations that led to net cash flow after dividend and capex of -$48 million.

Biosimilars and biologics manufacturing: building optionality beyond generics

The strategic center of the presentation was the biologics platform, anchored by CuraTeQ Biologics and the TheraNym contract manufacturing initiative. The message is not that these businesses will replace generics quickly, but that they can widen the growth runway and reduce reliance on periodic generic cycles.

CuraTeQ’s regulated-market progress is tangible. In the EEA, approvals include Zefylti, Dyrupeg, and Dazublys. In the UK, approvals include Zefylti, Dyrupeg, Dazublys, and Bevqlova. In Canada, Dyrupeg and Bevqlova have approvals. Filings include Bevqlova with EMA, and Dazublys and Zefylti with Health Canada. The company said BP16 Denosumab and BP11 Omalizumab are to be filed in 2026.

Aurobindo is also using partnerships to build commercialization reach. A licensing agreement was executed with STADA in March 2026 for distributing two EMA approved biosimilars in select EU territories including France and Germany. This matters because biosimilar launches require market access and scale, not just approvals.

Near-term milestones are defined. Omalizumab Phase 3 has been successfully completed, meeting primary endpoints in chronic spontaneous urticaria patients, enabling planned EMA and FDA filings by end of Q2 2026. Denosumab filing is planned by Q2 2026 with EMA followed by FDA. The company also noted supplies initiated in the UK and Europe for Dazublys, Zefypti, and Dyrupeg, following Bevqvola UK launch, with supplies to additional countries including France, Portugal, and Germany. In Canada, approvals for Dyrupeg and Bevqvola are in place, and two additional product filings are under review with approvals expected in 2026. Growth market expansion includes supplies initiated for tenders in Mexico for Zefypti, Dyrupeg, and Bevqvola, and four filings in Brazil.

Capacity is being built with a longer view. CuraTeQ is adding bulk manufacturing and filling capacities at Units 1 and 2 to align for 2028 and beyond. The opportunity framing is explicit: over 30 leading biologics, each generating USD 1 to 30 billion in revenues, are expected to lose patent protection between 2028 and 2035. CuraTeQ positioned its total addressable market over the next decade at USD 50 billion and pointed to easing regulatory barriers, including the idea that agencies such as EMA and the US FDA may move away from multimillion-dollar Phase 3 studies in some cases.

Alongside biosimilars, TheraNym represents a second pillar: biologics contract manufacturing. The company said TheraNym Unit 1 is a 60 kL integrated mammalian cell culture facility, with commissioning to be fully completed by end-2026. TheraNym also executed an additional product schedule with Merck Sharp and Dohme Singapore Trading, expanding an existing CMO relationship announced in May 2024. Under the schedule, TheraNym will build, operate, and supply drug substance to MSD.

The plan includes a dedicated greenfield drug substance facility, Unit 2, with an aggregate 60 kL mammalian cell-culture bioreactor capacity plus downstream purification infrastructure. Estimated capex for Unit 2 is USD 150 to 175 million. Management framed this as positioning Aurobindo within the global biologics supply chain by 2030, supported by an outsourcing market growing at a CAGR of over 12 percent.

What investors can take away

Q4 FY26 was a quarter of steady delivery rather than dramatic acceleration. Consolidated revenue grew mid single digits, profits edged higher, and gross margins improved, but overhead growth and mix kept EBITDA nearly flat. The headline numbers look calm, but the segment detail is important. Europe has become the strongest growth driver in the current cycle, while the US is moving through a softer period that management attributes to seasonality and the absence of transient sales.

The more durable signal is in capital allocation and portfolio evolution. Aurobindo is continuing to invest in R and D and capacity, with a stated focus on biosimilars and specialty products, while maintaining a strong net cash position. CuraTeQ’s approvals and filings in Europe, the UK, and Canada, combined with near-term filing milestones for Omalizumab and Denosumab, show a program moving from development into commercialization. TheraNym adds a parallel route to participate in biologics growth through manufacturing partnerships.

The quarter’s theme is disciplined execution with visible optionality. The generics base is being defended through launches and approvals, Europe is expanding share, and the biologics platform is being built with clear milestones. For investors, the next set of signals to watch will be the trajectory of the US base business, the pace of biosimilar filings in 2026, and how capex translates into scale without pressuring margins for too long.